Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228033 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of Supplemental Calcium in Preventing Postpartum Depression
A Phase 4 study of Depression and Depression, Postpartum, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 238
- Enrollment target
- 1
- Study location
NCT00228033 is a Phase 4 study of Depression and Depression, Postpartum that has completed, run by Oregon Health and Science University. The registered enrollment target is 238 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00228033, a Phase 4 study of Depression and Depression, Postpartum, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 238 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of taking supplemental calcium while pregnant in reducing the risk of postpartum depression.
Conditions Studied
Interventions
- DRUG Elemental calcium (as carbonate)
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2002-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00228033
The ClinicalTrials.gov registry entry for NCT00228033 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (70% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Elemental calcium (as carbonate) is the first listed.
NCT00228033 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00228033 about?
NCT00228033 is a clinical study titled "Effectiveness of Supplemental Calcium in Preventing Postpartum Depression". This study will evaluate the effectiveness of taking supplemental calcium while pregnant in reducing the risk of postpartum depression.
What is the current status of trial NCT00228033?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 238 participants. The study started on 2002-04. Estimated completion is 2007-08.
What conditions does trial NCT00228033 study?
This clinical trial studies the following conditions: Depression, Depression, Postpartum.
What interventions are being tested in trial NCT00228033?
The interventions under investigation include: Elemental calcium (as carbonate) (DRUG).
Who is sponsoring clinical trial NCT00228033?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00228033 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.